Vaxcyte, Inc. — Director's Dealing 2023

Jan 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-12-30

Reporting Person: Eydelman Mikhail (SVP, Gen Counsel & Corp Sec)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-30	Stock Option (right to buy)	$47.95	A	27500	Acquired	2032-12-30	Common Stock (27500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8032	Direct

Footnotes

F1: Includes 532 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2022.

F2: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.